Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Oct. 28, 2011 - PRLog -- GlobalData estimated the global anti-hypertension therapeutics market to be worth $30.3 billion in 2010, having grown at a CAGR of 4.2% from $24.6 billion in 2005. The market is forecast to decline at a Compound Annual Growth Rate (CAGR) of 2.3% to be worth $25.1 billion in 2018. The decline in the antihypertension therapeutics market during the forecast period is due to the increasing availability of generic anti-hypertension drugs. The major drugs that are set to lose their patent exclusivity in the forecast period to 2018 are spread across various classes of therapy for the treatment of hypertension, namely angiotensin receptor blockers (ARBs), angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), α-blockers, β-blockers (BB), diuretics and direct rennin inhibitors (DRI).

The launch of the first-in-class product Tekturna (aliskiren) has advanced the treatment of hypertension and heart failure. Tekturna is known as Rasilez outside the US and will lose its patent exclusivity in 2018. However, the patent expiry for ARBs such as Diovan (valsartan), Avapro (irbesartan) and Atacand (candesartan) is imminent in 2012. Other ARBs losing their patent exclusivity include Micardis (telmisartan) in 2014 and Benicar (olmesartan) in 2016. The patent expiration of blockbuster ARB drugs such as Diovan, Avapro and Atacand (candesartan) will result in the decline of the anti-hypertension therapeutics market. The anti-hypertension therapeutics market growth was also affected by the patent expiry of Cozaar (losartan) in 2010. The sales of ACE inhibitors are declining due to the availability of generics and competition from ARBs. Novartis’ Diovan will witness a major decline in its market share following its patent expiry. The pipeline for anti-hypertension therapeutics is also weak. There is a lack of emerging therapies with novel mechanisms of action in Phase III of clinical development. Consequently, the anti-hypertension therapeutics market growth will remain constrained throughout the forecast period to 2018.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData found that current competition in the anti-hypertension therapeutics market is very strong and provides a vast array of treatment options for hypertension. The market is well served by drugs from various therapeutics classes such as ARBs, ACE inhibitors, CCBs, α-blockers, BB, DRI and diuretics.
Diuretics are cost effective and are most widely prescribed in combination with ARBs and ACE inhibitors.
A number of other combination products are also present in the market such as ARBs or ACE inhibitors with CCBs, α-blockers or BBs. However, the anti-hypertension therapeutics market is set to witness a number of major patent expiries during the forecast period, such as Diovan and Avapro (ARBs) in 2012, Micardis in 2014, Benicar in 2016 and the DRI Tekturna in 2018. The anti-hypertension therapeutics market will remain highly genericized moving towards a market share war until new products are launched.

GlobalData, the industry analysis specialist, has released its new report, “Anti-Hypertension Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global anti-hypertension therapeutics market. The report identifies the key trends shaping and driving the global anti-hypertension therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anti-hypertension therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Anti...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.